DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (DRIO) on September 18, 2025. The filing addresses a material modification to the rights of security holders regarding the Company's preferred stock classes.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than operational financial performance.
Material Changes
On September 18, 2025, following approval by the Board of Directors and a majority vote of relevant preferred stockholders, the Company filed amended and restated Certificates of Designation for the following series:
- Series A-1 Preferred Stock
- Series C and Series C-2 Preferred Stock
- Series D, Series D-1, Series D-2, and Series D-3 Preferred Stock
Key amendments include:
- Accelerated Conversion: The mandatory conversion period for Series C and Series D preferred stock into common stock (or pre-funded warrants at the holder's election) was accelerated, effective September 18, 2025.
- Conversion Options: Series A-1 holders were granted the option to receive pre-funded warrants in lieu of common stock upon conversion.
- Dividend Treatment: Holders will receive all accrued and unpaid dividends, including dividend shares or payment-in-kind shares, in addition to conversion shares, subject to beneficial ownership blockers.
- No New Issuance: The filings amended existing terms; no additional securities were issued or sold as a result of this action.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed relates to the dilution impact of the accelerated conversion of preferred stock into common stock or pre-funded warrants. The full terms of the amendments are detailed in the exhibits filed with this report.
Investor Verification Checklist
- Verify the exact number of shares of each preferred series (A-1, C, C-2, D, D-1, D-2, D-3) outstanding prior to conversion.
- Review the specific conversion ratios and the terms of the pre-funded warrants offered as an alternative to common stock.
- Assess the total value of accrued and unpaid dividends to be distributed to preferred holders.
- Examine the "beneficial ownership blockers" mentioned to understand potential limitations on the conversion process.
- Review the full text of Exhibits 3.1 through 3.7 for detailed legal terms of the amended certificates.